- You can view the full Gilead Ratings Report.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Gilead ( GILD) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.3%. By the end of trading, Gilead rose $0.61 (1.1%) to $57.75 on average volume. Throughout the day, 9,097,691 shares of Gilead exchanged hands as compared to its average daily volume of 11,422,900 shares. The stock ranged in a price between $57.11-$57.77 after having opened the day at $57.37 as compared to the previous trading day's close of $57.14. Other companies within the Drugs industry that increased today were: Synthetic Biologics ( SYN), up 9.8%, Insmed ( INSM), up 9.4%, IntelliPharmaCeutics International ( IPCI), up 8.8% and Star Scientific ( STSI), up 8.1%. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $88.0 billion and is part of the health care sector. Shares are up 57.0% year to date as of the close of trading on Tuesday. Currently there are 18 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold. TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, solid stock price performance, reasonable valuation levels and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.
